{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:51:51Z","timestamp":1784206311788,"version":"3.55.0"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"\n Importance<\/jats:title>\n Currently, there are no treatments approved by the US Food and Drug Administration for juvenile localized scleroderma (JLS), a rare disease. While methotrexate (MTX) is regularly used as a first-line therapy, emerging data from case series and applications in systemic sclerosis suggest that mycophenolate mofetil (MMF) may be clinically comparable, with potential benefits in tolerability and adherence.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare clinical outcomes of patients with JLS treated with MTX and MMF using standardized clinical outcome measures.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective cohort study of patients with clinician-diagnosed JLS who were enrolled in the National Registry of Childhood Onset Scleroderma was conducted at UPMC Children\u2019s Hospital of Pittsburgh. Data were from January 2010 to January 2023 and first analyzed in April 2023. All patients were evaluated and followed up by the same physician. Patients were included if they had disease onset before age 18 years and a localized scleroderma diagnosis and enrollment in the National Registry of Childhood Onset Scleroderma before age 21 years. Patients were required to be receiving MTX monotherapy, MMF monotherapy, or combination therapy (CT) of the 2 for their localized scleroderma.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Patients were treated with MTX, MMF, or CT as prescribed by the examining physician.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n This study measured comparative medication treatment response through associations with disease activity, as measured using the Localized Scleroderma Cutaneous Assessment Tool.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 114 patients, 77 (67.5%) were female, and the median (IQR) age at onset was 8.3 (5.4-11.2) years. The MTX, MMF, and CT groups included 68 (59.6%), 28 (24.6%), and 18 patients (15.8%), respectively. There were no significant differences in baseline demographic characteristics, disease subtype, or disease severity between groups, but patients in the MMF group had longer disease duration. Mixed-effects modeling showed statistically significant decreases in activity across all groups (\u03b2\u2009=\u2009\u22120.14; 95% CI, \u22120.62 to 0.33). A Kaplan-Meier analysis showed no significant difference in disease flare rate over the follow-up interval (hazard ratio, 0.85; 95% CI, 0.51-1.33). However, patients treated with MTX compared with those treated with MMF had significantly higher rates of fatigue (47% vs. 11%,\n P<\/jats:italic>\n = .001) and nausea (60% vs. 7%;\n P<\/jats:italic>\n = .001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The study results suggest that MMF demonstrated a similar response to treatment as MTX in reducing disease activity in JLS, with comparable flare rates and improved tolerability. These initial findings support MMF as a potential candidate for first-line treatment of JLS. Prospective, randomized, noninferiority trials are warranted to confirm these results and guide future treatment recommendations.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2025.5662","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T16:31:10Z","timestamp":1769617870000},"page":"271","source":"Crossref","is-referenced-by-count":1,"title":["Methotrexate and Mycophenolate Mofetil and Clinical Response in Juvenile Localized Scleroderma"],"prefix":"10.1001","volume":"162","author":[{"given":"Elena C.","family":"de Rosas","sequence":"first","affiliation":[{"name":"University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin C.","family":"Wang","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina K.","family":"Zigler","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn S.","family":"Torok","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"},{"name":"Department of Pediatrics, Division of Pediatric Rheumatology, University of Pittsburgh Medical Center Children\u2019s Hospital of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"doi250070r1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/acr2.1019","article-title":"Baseline description of the juvenile localized scleroderma subgroup from the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry.","volume":"1","author":"Wu","year":"2019","journal-title":"ACR Open Rheumatol"},{"issue":"4","key":"doi250070r2","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.pcl.2018.04.002","article-title":"Scleroderma in children and adolescents: localized scleroderma and systemic sclerosis.","volume":"65","author":"Li","year":"2018","journal-title":"Pediatr Clin North Am"},{"issue":"2","key":"doi250070r3","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3899\/jrheum.110210","article-title":"Methotrexate and corticosteroids in the treatment of localized scleroderma: a standardized prospective longitudinal single-center study.","volume":"39","author":"Torok","year":"2012","journal-title":"J Rheumatol"},{"issue":"8","key":"doi250070r4","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/acr.21687","article-title":"Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma.","volume":"64","author":"Li","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"doi250070r5","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.3899\/jrheum.190311","article-title":"Initial results from a pilot comparative effectiveness study of three methotrexate-based consensus treatment plans for juvenile localized scleroderma.","volume":"47","author":"Li","year":"2020","journal-title":"J Rheumatol"},{"issue":"5","key":"doi250070r6","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/j.1365-2133.2006.07497.x","article-title":"Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children.","volume":"155","author":"Weibel","year":"2006","journal-title":"Br J Dermatol"},{"issue":"7","key":"doi250070r7","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/art.30264","article-title":"Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial.","volume":"63","author":"Zulian","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"6","key":"doi250070r8","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.jaad.2012.03.036","article-title":"A long-term follow-up study of methotrexate in juvenile localized scleroderma (morphea).","volume":"67","author":"Zulian","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi250070r9","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1365-2133.2011.10535.x","article-title":"Relapse after systemic treatment in paediatric morphoea.","volume":"166","author":"Mirsky","year":"2012","journal-title":"Br J Dermatol"},{"issue":"5","key":"doi250070r10","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1111\/bjd.17312","article-title":"Prediction of disease relapse in a cohort of paediatric patients with localized scleroderma.","volume":"180","author":"Kurzinski","year":"2019","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi250070r11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/bjd.16449","article-title":"Children with facial morphoea managing everyday life: a qualitative study.","volume":"179","author":"Stasiulis","year":"2018","journal-title":"Br J Dermatol"},{"issue":"11","key":"doi250070r12","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1093\/rheumatology\/kep244","article-title":"Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil.","volume":"48","author":"Martini","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"doi250070r13","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1001\/jamadermatol.2020.0035","article-title":"Evaluation of the effectiveness and tolerability of mycophenolate mofetil and mycophenolic acid for the treatment of morphea.","volume":"156","author":"Arthur","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"4","key":"doi250070r14","doi-asserted-by":"publisher","first-page":"510","DOI":"10.2340\/00015555-2297","article-title":"Use of mycophenolate mofetil in patients with severe localized scleroderma resistant or intolerant to methotrexate.","volume":"96","author":"Mertens","year":"2016","journal-title":"Acta Derm Venereol"},{"issue":"212","key":"doi250070r15","doi-asserted-by":"publisher","DOI":"10.1007\/s42399-023-01546-5","article-title":"A scoping review of the efficacy and safety of methotrexate compared to mycophenolate mofetil in the treatment of juvenile localized scleroderma in children and young adults.","volume":"5","author":"Singhal","year":"2023","journal-title":"SN Compr Clin Med"},{"key":"doi250070r16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.12688\/amrcopenres.13008.1","article-title":"Prior elicitation of the efficacy and tolerability of methotrexate and mycophenolate mofetil in juvenile localised scleroderma.","volume":"3","author":"Desai","year":"2021","journal-title":"AMRC Open Res"},{"issue":"3","key":"doi250070r17","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1093\/rheumatology\/keaa392","article-title":"Mycophenolate mofetil for methotrexate-resistant juvenile localized scleroderma.","volume":"60","author":"Martini","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"doi250070r18","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1136\/annrheumdis-2018-214697","article-title":"Consensus-based recommendations for the management of juvenile localised scleroderma.","volume":"78","author":"Zulian","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"doi250070r19","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/jdv.14458","article-title":"European Dermatology Forum S1\u2014guideline on the diagnosis and treatment of sclerosing diseases of the skin, part 1: localized scleroderma, systemic sclerosis and overlap syndromes.","volume":"31","author":"Knobler","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"doi250070r20","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1108623","article-title":"Morphea: the 2023 update.","volume":"10","author":"Papara","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"doi250070r21","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1097\/01.bor.0000245727.40630.c3","article-title":"Localized scleroderma.","volume":"18","author":"Laxer","year":"2006","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"doi250070r22","first-page":"650","article-title":"Localized scleroderma severity index and global assessments: a pilot study of outcome instruments.","volume":"35","author":"Arkachaisri","year":"2008","journal-title":"J Rheumatol"},{"issue":"12","key":"doi250070r23","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.3899\/jrheum.081284","article-title":"The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures.","volume":"36","author":"Arkachaisri","year":"2009","journal-title":"J Rheumatol"},{"issue":"2","key":"doi250070r24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/rheumatology\/kep361","article-title":"Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study.","volume":"49","author":"Arkachaisri","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"doi250070r25","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jaad.2013.02.007","article-title":"The localized scleroderma cutaneous assessment tool: responsiveness to change in a pediatric clinical population.","volume":"69","author":"Kelsey","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi250070r26","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/bjd.18097","article-title":"Using the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) to classify morphoea by severity and identify clinically significant change.","volume":"182","author":"Teske","year":"2020","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi250070r27","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/bjd.18879","article-title":"Exploring the impact of paediatric localized scleroderma on health-related quality of life: focus groups with youth and caregivers.","volume":"183","author":"Zigler","year":"2020","journal-title":"Br J Dermatol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2844463\/jamadermatology_de_rosas_2026_oi_250070_1772642720.22235.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:00:20Z","timestamp":1773846020000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2844463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2025.5662","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}